NDAORALTABLET
Approved
Jan 2011
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
Drug data last refreshed 5h ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VIIBRYD (vilazodone HCl) is an oral small-molecule antidepressant approved for major depressive disorder in adults. It functions as a selective serotonin reuptake inhibitor (SSRI) with 5-HT1A receptor partial agonist activity, offering a dual mechanism to address both serotonin availability and receptor signaling.
$0.017BPart D
LOE ApproachingDeclining
Approaching loss of exclusivity with modest Medicare spending signals a contracting franchise requiring defensive commercial strategies and team optimization.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on VIIBRYD offers exposure to mature brand management and lifecycle defense strategies in psychiatry, a stable therapeutic area. However, the approaching LOE and modest linked job count suggest limited career expansion opportunity; roles emphasize optimization and managed decline rather than growth.
Brand ManagerProduct Manager
Worked on VIIBRYD at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.